Ponsegromab (PF‐06946860) is a potent and highly selective humanized monoclonal antibody directed against GDF‐15 that is currently being investigated in patients with cancer, cachexia and elevated circulating concentrations of GDF‐15. Here, GDF15 is linked to cancer.